Michael Laffan is Professor of Haemostasis and Thrombosis in the department of haematology.He trained in medicine at the University of Oxford and trained in haematology at the Hammersmith and Royal Free hospitals. His principal research interests are the structure function relationship of von Willebrand factor, in particular the role of glycosylation, and the mechanisms and regulation of thrombin generation. He is director of the Hammersmith Hospital Haemophilia centre and is responsible for postgraduate education in haematology.
et al., 2021, Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination, Journal of Neurology, Neurosurgery and Psychiatry, ISSN:0022-3050
et al., 2021, Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK - a multicentre observational study, British Journal of Haematology, ISSN:0007-1048
The ATTACC, ACTIV-4a, and REMAP-CAP Investigators, 2021, Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19, New England Journal of Medicine, Vol:385, ISSN:0028-4793, Pages:790-802
The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, 2021, Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19, New England Journal of Medicine, Vol:385, ISSN:0028-4793, Pages:777-789
et al., 2021, Impact of thrombosis and bleeding in patients with severe COVID-19 versus other viral pneumonias in the context of extracorporeal membrane oxygenation, Seminars in Thrombosis and Hemostasis, ISSN:0094-6176, Pages:1-6